| Literature DB >> 30377557 |
Ruirui Wang1,2,3,4, Li Yang1,2,3, Chaoqi Zhang1,2,3, Ruijie Wang1,2,3, Zhen Zhang1,2,3, Qianyi He1,2,3, Xinfeng Chen1,2,3, Bin Zhang5, Zhihai Qin4, Liping Wang2,3, Yi Zhang1,2,3,6.
Abstract
Non-small cell lung cancer (NSCLC) accounts for the majority of all lung cancer cases, which is the leading cause of cancer deaths worldwide. IL-17░A, the major effector cytokine derived from Th17 cells, is a key cytokine in tumor pathogenesis and modulates tumor progression. We aimed to identify whether IL-17░A derived from Th17 cells promotes the progression of NSCLC. Here we found that the level of Th17 cells was increased in NSCLC and IL-17░A was mainly produced by CD4+ cells (Th17 cells) in NSCLC. IL-17░A enhanced the migration, invasion and stemness of NSCLC via STAT3/NF-κB/Notch1 signaling. Blockade of this signaling inhibited the migration, invasion and stemness of NSCLC mediated by IL-17░A. Th17 cells in NSCLC were closely associated with poor prognosis of NSCLC patients. Our results indicated that Th17 cell-derived IL-17░A plays an important role in tumor progression of NSCLC via STAT3/NF-κB/Notch1 signaling. Therefore, therapeutic strategies against this pathway would be valuable to be developed for NSCLC treatment.Entities:
Keywords: Th17 cells; Tumor microenvironment; interleukin-17A (IL-17A); non-small cell lung cancer (NSCLC); tumor progression
Year: 2018 PMID： 30377557 PMCID： PMC6205058 DOI： 10.1080/2162402X.2018.1461303
Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110